Solathin (Potato protein extract)

Solathin is a proprietary potato protein extract (Solanum tuberosum) standardized for protease inhibitor II (PI2), a peptide that stimulates cholecystokinin (CCK) release to signal satiety. It is processed to reduce glycoalkaloids such as solanine and chaconine, making it safer than crude potato protein while delivering a complete amino acid profile with an Amino Acid Score (AAS) ≥1.

Origin & History

Solathin is a branded potato protein extract derived from potato juice (Solanum tuberosum) through a proprietary process involving microfiltration, ultrafiltration, glycoalkaloid removal, and spray drying. The final powder contains 30-91% pure protein with an amino acid score (AAS) ≥1, indicating a complete protein profile.

Historical & Cultural Context

No traditional medicinal use of potato protein extracts is documented. While potatoes have been cultivated as a food staple since the 16th century, protein isolates like Solathin are modern industrial inventions developed through advanced extraction technologies.

Health Benefits

• Weight management support through potential satiety mechanisms (no clinical evidence available)
• High-quality protein source with complete amino acid profile (AAS ≥1)
• Glycoalkaloid-reduced formulation for improved safety profile
• Potential antiproliferative properties (only in-vitro extraction studies)
• Natural plant-based protein alternative (30-91% pure protein content)

How It Works

Solathin's primary bioactive compound, Protease Inhibitor II (PI2), inhibits the digestive enzyme chymotrypsin in the small intestine, triggering a feedback loop that stimulates enteroendocrine I-cells to secrete cholecystokinin (CCK). Elevated CCK binds to CCK-A receptors in the gastrointestinal tract and hypothalamus, slowing gastric emptying and transmitting satiety signals via the vagus nerve to the brain. Additionally, Solathin provides a complete essential amino acid profile, which may further modulate appetite-regulating hormones including peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) through protein-induced satiety pathways.

Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically on Solathin were identified in the available research. The evidence base consists solely of extraction methodology studies and in-vitro characterization of potato proteins, with no clinical outcome data on weight management or other health effects.

Clinical Summary

Human clinical evidence specifically for Solathin (the branded PI2-enriched potato protein extract) is extremely limited, with no large-scale randomized controlled trials publicly available as of 2024. A small pilot study on potato PI2 suggested increased CCK levels and reduced appetite scores in healthy adults at doses around 1–5 g, but sample sizes were insufficient for definitive conclusions. In-vitro studies have demonstrated PI2's inhibitory activity against chymotrypsin, and animal models show reduced food intake following PI2 administration, providing mechanistic plausibility. The antiproliferative properties referenced in some supplier literature are based solely on in-vitro cell culture data and have not been replicated in human or animal trials, significantly limiting their clinical relevance.

Nutritional Profile

Solathin is a proprietary potato protein extract derived from Solanum tuberosum processing water (potato fruit juice); it is enriched in protease inhibitor II proteins (PI2) and patatin-class proteins with a favorable amino acid profile including high lysine content, and functions as a satiety-promoting ingredient by stimulating cholecystokinin (CCK) release from intestinal enteroendocrine cells.

Preparation & Dosage

No clinically studied dosage ranges are available for Solathin. The product is supplied as a powder containing 30-91% pure protein, but no human trials have established effective doses. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Green tea extract, Garcinia cambogia, Chromium picolinate, Glucomannan, CLA

Safety & Interactions

Solathin is manufactured with a glycoalkaloid-reduction process to minimize solanine and chaconine content, both of which are toxic at high concentrations and found naturally in potato plants; however, consumers with known nightshade (Solanaceae) sensitivities or allergies should exercise caution. No serious adverse events have been formally documented in published human trials at typical supplemental doses (1–5 g/day), though gastrointestinal discomfort such as bloating or nausea may occur, particularly at higher doses. Because Solathin may slow gastric emptying via CCK elevation, it could theoretically interact with medications that require precise gastric absorption timing, such as certain thyroid medications (levothyroxine) or oral diabetes drugs; patients on these medications should consult a physician before use. Safety data during pregnancy and lactation is absent, so use is not recommended in these populations until further research is available.